← Back to Patent Explorer
US4032659A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of viral chemoprophylaxis

Assignee: Wyeth LLC
•
Filing: 1975-06-26
•
Granted: 1977-06-28
•
Expires: 1995-06-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract It has been found that compounds having a stereochemically unencumbered access to a nitrogen-nitrogen bond have antiviral activity in extremely low dose ranges. Hydrazine, hydrazine derivatives and related compounds have been found to be active in protecting animals against disease caused by both DNA and RNA type viruses at doses of about 250 picograms to 250 micrograms per kilograms of host body weight.

Inventors

  • 👤 Charles Paul Hegarty
  • 👤 Helen C. Pietryk

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 18:46
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/02; A61K31/00; A61K31/13; A61K31/15; A61K31/33; A61K31/395; A61K31/495; A61K31/50; Y; Y02; Y02A; Y02A50/00; Y02A50/30

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 132 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is a member of the class consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound is selected from the class consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. acetoacetic acid, ethylester, thiosemicarbazone F. cyclohexanone, thiosemicarbazone G. cyclobutanone, thiosemicarbazone H. 2-indanone, thiosemicarbazone I. 2-indanone, 4-allythiosemicarbazone J. cyclopentanone, o-tolylthiosemicarbazone K. adamantyl thiosemicarbazide L. thiosemicarbazide M. methisazone N. semicarbazide and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Independent Claim 132 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is a member of the class consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound is selected from the class consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. acetoacetic acid, ethylester, thiosemicarbazone F. cyclohexanone, thiosemicarbazone G. cyclobutanone, thiosemicarbazone H. 2-indanone, thiosemicarbazone I. 2-indanone, 4-allythiosemicarbazone J. cyclopentanone, o-tolylthiosemicarbazone K. adamantyl thiosemicarbazide L. thiosemicarbazide M. methisazone N. semicarbazide and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim 14 words
A method as defined in claim 1 in which the compound is administered orally.
Claim 4
Dependent Claim 22 words
A method as defined in claim 1 in which the compound is administered in the form of a tablet, capsule or solution.
Claim 5
Dependent Claim 17 words
A method as defined in claim 1 in which the compound is administered at 48 hour intervals.
Claim 6
Dependent Claim 24 words
A method as defined in claim 1 in which the compound is administered either before or after infection or both before and after infection.
Claim 7
Independent Claim 110 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is selected from the group consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound selected from the group consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. cyclohexanone, thiosemicarbazone F. cyclobutanone, thiosemicarbazone G. cyclopentanone, o-tolylthiosemicarbazone and the pharmaceutically acceptable acid addition salts thereof.
Claim 8
Independent Claim 110 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is selected from the group consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound selected from the group consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. cyclohexanone, thiosemicarbazone F. cyclobutanone, thiosemicarbazone G. cyclopentanone, o-tolylthiosemicarbazone and the pharmaceutically acceptable acid addition salts thereof.
Claim 9
Dependent Claim 14 words
A method as defined in claim 6 in which the compound is administered orally.
Claim 10
Dependent Claim 22 words
A method as defined in claim 6 in which the compound is administered in the form of a tablet, capsule or solution.
Claim 11
Dependent Claim 17 words
A method as defined in claim 6 in which the compound is administered at 48 hour intervals.
Claim 12
Dependent Claim 24 words
A method as defined in claim 6 in which the compound is administered either before or after infection or both before and after infection.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-06-27 1980-12-27 1981-06-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-06-27 1984-12-27 1985-06-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-06-27 1988-12-27 1989-06-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag